BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nexium (Esomeprazole) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nexium (Esomeprazole)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07312370-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Nexium (Esomeprazole): Phase 4 readout est. (NCT07312370)
DESCRIPTION:Nexium (Esomeprazole)\, phase 4.\nStudy: Esomeprazole Plus Sucr
 alfate for Post-ESD Ulcer Healing\nEstimated primary completion: 20 Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/esomeprazole
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 12370
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06733675-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nexium (Esomeprazole): Phase 1 readout est. (NCT06733675)
DESCRIPTION:Nexium (Esomeprazole)\, phase 1.\nStudy: Safety and PK of Cefti
 buten-ledaborbactam Etzadroxil Fixed-dose Combination\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/esomeprazole#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06733675
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790549-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Nexium (Esomeprazole): Phase na readout est. (NCT07790549)
DESCRIPTION:Nexium (Esomeprazole)\, phase na.\nStudy: Mirgeal® Gel as Add-
 on Therapy to Esomeprazole in Adults With Non-Erosive Gastroesophageal Ref
 lux Disease\nEstimated primary completion: 29 January 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/esomeprazole#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07790549
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02373280-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nexium (Esomeprazole): Phase na readout est. (NCT02373280)
DESCRIPTION:Nexium (Esomeprazole)\, phase na.\nStudy: The Efficacy of the 7
  Days Tailored Therapy as the 1st Eradication of H. Pylori Infection\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/esomeprazole#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02373280
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896577-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nexium (Esomeprazole): Phase na readout est. (NCT07896577)
DESCRIPTION:Nexium (Esomeprazole)\, phase na.\nStudy: Prophylactic PPI Use 
 After EUS-GE Procedure\nEstimated primary completion: June 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/esomeprazole#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07896577
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746934-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270827
DTEND;VALUE=DATE:20270828
SUMMARY:Nexium (Esomeprazole): Phase na readout est. (NCT07746934)
DESCRIPTION:Nexium (Esomeprazole)\, phase na\, Helicobacter pylori Infectio
 n.\nStudy: Metronidazole- Versus Tinidazole-Based Bismuth Quadruple Therap
 y for Helicobacter Pylori Eradication\nEstimated primary completion: 27 Au
 gust 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/esomeprazo
 le#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7746934
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06955520-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271210
DTEND;VALUE=DATE:20271211
SUMMARY:Nexium (Esomeprazole): Phase na readout est. (NCT06955520)
DESCRIPTION:Nexium (Esomeprazole)\, phase na.\nStudy: Vonaprazan Versus Eso
 meprazole for Healing of LA Grade B or Higher Esophagitis After POEM\nEsti
 mated primary completion: 10 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/esomeprazole#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06955520
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120803-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nexium (Esomeprazole): Phase 2 readout est. (NCT06120803)
DESCRIPTION:Nexium (Esomeprazole)\, phase 2.\nStudy: Esomeprazole and Radia
 tion Induced Esophagitis\nEstimated primary completion: 30 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/esomeprazole#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06120803
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05320796-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nexium (Esomeprazole): Phase 4 readout est. (NCT05320796)
DESCRIPTION:Nexium (Esomeprazole)\, phase 4.\nStudy: The Bioavailability an
 d Effect on Pouch pH of Esomeprazole After Gastric Bypass\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/esomeprazole#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05320796
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04448028-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Nexium (Esomeprazole): Phase 4 readout est. (NCT04448028)
DESCRIPTION:Nexium (Esomeprazole)\, phase 4.\nStudy: Stop of Proton-pump In
 hibitor Treatment in Patients With Liver Cirrhosis - a Double-blind\, Plac
 ebo-controlled Trial\nEstimated primary completion: February 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/esomeprazole#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04448028
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04527055-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nexium (Esomeprazole): Phase 4 readout est. (NCT04527055)
DESCRIPTION:Nexium (Esomeprazole)\, phase 4\, Helicobacter pylori Infection
 .\nStudy: The Efficacy of 10-day and 14-day Bismuth-based Quadruple Therap
 y in First-line H. Pylori Eradication\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/esomeprazole
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045
 27055
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866668-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nexium (Esomeprazole): Phase 2 readout est. (NCT03866668)
DESCRIPTION:Nexium (Esomeprazole)\, phase 2.\nStudy: A Study of Esomeprazol
 e in Children With Autism\nEstimated primary completion: December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/esomeprazole#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT03866668
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06903585-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nexium (Esomeprazole): Phase 2 readout est. (NCT06903585)
DESCRIPTION:Nexium (Esomeprazole)\, phase 2.\nStudy: Non Steroidal Anti-inf
 lammatory Drugs in the Prevention of Bone Pain Flares After Palliative Rad
 iotherapy\nEstimated primary completion: April 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/esomeprazole#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06903585
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07144657-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nexium (Esomeprazole): Phase 2 readout est. (NCT07144657)
DESCRIPTION:Nexium (Esomeprazole)\, phase 2.\nStudy: Prospective Study of F
 rontline Antibiotics Therapy in the Treatment of Early-stage HP-negative G
 astric MALT Lymphoma\nEstimated primary completion: 31 December 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/esomeprazole#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07144657
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06509139-4027@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Nexium (Esomeprazole): Phase 4 readout est. (NCT06509139)
DESCRIPTION:Nexium (Esomeprazole)\, phase 4\, Helicobacter pylori Infection
 .\nStudy: Optimal Duration of Bismuth Quadruple Therapy for Helicobacter P
 ylori Eradication in Females As Compared with Males\nEstimated primary com
 pletion: 31 July 2032. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/esomeprazole#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06509139
URL:https://assetmemo.bio/drug/esomeprazole#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
